eMedicine Specialties > Urology > Incontinence

Urinary Incontinence, Nonsurgical Therapies: Follow-up

Author: Raymond Rackley, MD, Professor of Surgery, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Staff Physician, Center for Pelvic Medicine and Pelvic Reconstruction, Glickman Urological Institute, Cleveland Clinic Foundation
Coauthor(s): Sandip P Vasavada, MD, Physician, Center for Female Pelvic Medicine and Genitourinary Reconstructive Surgery, The Glickman Urological and Kidney Institute; Joint Appointment with Women's Institute, Cleveland Clinic; Michael S Ingber, MD, Clinical Fellow, Glickman Urological and Kidney Institute of the Cleveland Clinic; Farzeen Firoozi, MD, Clinical Fellow, Center for Female Urology and Pelvic Reconstructive Surgery, Glickman Urological and Kidney Institute of the Cleveland Clinic
Contributor Information and Disclosures

Updated: May 6, 2009

Follow-up

Further Outpatient Care

Complications

  • Prolonged contact of urine with the unprotected skin causes contact dermatitis and skin breakdown. If left untreated, these skin disorders may lead to pressure sores and ulcers, possibly resulting in secondary infections. For individuals with a decompensated bladder that does not empty well, the postvoid residual urine can lead to overgrowth of bacteria and subsequent UTI.
  • Long-term indwelling catheters may cause recurrent bladder infection, bladder stones, ascending pyelonephritis, and urethral erosion. The use of intermittent catheterization may result in bladder infections or urethral injury. Long-term use of suprapubic tubes may result in bladder spasms, bladder stone formation, and bladder infection.
  • Potential problems unique to suprapubic catheters include skin infection, hematoma, bowel injury, and problems with catheter reinsertion.
  • Complications of intermittent catheterization include bleeding, infection, and urethral injury.
  • Untreated UTIs may lead to urosepsis and death.

Prognosis

  • The prognosis of a patient with incontinence is excellent with today's health care. With improvement in information technology, well-trained medical staff, and advances in modern medical knowledge, patients with incontinence should not experience the morbidity and mortality of the past. Although the ultimate well being of a patient with incontinence depends on the underlying condition that has precipitated urinary incontinence, urinary incontinence itself is easily treated and prevented by properly trained health care individuals.

Patient Education

Miscellaneous

Medicolegal Pitfalls

  • Failure to diagnose and treat urinary retention may result in adverse consequences.
  • Rule out narrow-angle glaucoma prior to prescribing an anticholinergic agent. Narrow-angle glaucoma may be converted to open-angle glaucoma by an experienced ophthalmologist.
  • When a patient is taking an anticholinergic agent, monitor these patients to prevent pharmacologically induced urinary retention.
 


More on Urinary Incontinence, Nonsurgical Therapies

Overview: Urinary Incontinence, Nonsurgical Therapies
Differential Diagnoses & Workup: Urinary Incontinence, Nonsurgical Therapies
Treatment & Medication: Urinary Incontinence, Nonsurgical Therapies
Follow-up: Urinary Incontinence, Nonsurgical Therapies
Multimedia: Urinary Incontinence, Nonsurgical Therapies
References

References

  1. Fultz NH, Herzog AR, Raghunathan TE. Prevalence and severity of urinary incontinence in older African American and Caucasian women. J Gerontol A Biol Sci Med Sci. Jun 1999;54(6):M299-303. [Medline].

  2. Freeman EW, Grisso JA, Berlin J. Symptom reports from a cohort of African American and white women in the late reproductive years. Menopause. Jan-Feb 2001;8(1):33-42. [Medline].

  3. Howard D, Delancey JO, Tunn R. Racial differences in the structure and function of the stress urinary continence mechanism. Obstet Gynecol. May 2000;95(5):713-7. [Medline].

  4. Sears CL, Wright J, O'Brien J, Jezior JR, Hernandez SL, Albright TS, et al. The racial distribution of female pelvic floor disorders in an equal access health care system. J Urol. Jan 2009;181(1):187-92. [Medline].

  5. Daneshgari F, Imrey PB, Risendal B, Dwyer A, Barber MD, Byers T. Differences in urinary incontinence between Hispanic and non-Hispanic white women: a population-based study. BJU Int. Mar 2008;101(5):575-9. [Medline].

  6. Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. Sep 17 2008;300(11):1311-6. [Medline].

  7. Moore KN, Schieman S, Ackerman T, Dzus HY, Metcalfe JB, Voaklander DC. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology. Jan 2004;63(1):150-4. [Medline].

  8. Burgio KL, Locher JL, Goode PS. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. Dec 16 1998;280(23):1995-2000. [Medline].

  9. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. Apr 2001;76(4):358-63. [Medline].

  10. Butler RN, Maby JI, Montella JM. Urinary incontinence: primary care therapies for the older woman. Geriatrics. Nov 1999;54(11):31-4, 39-40, 43-4. [Medline].

  11. Comiter CV. Surgery Insight: surgical management of postprostatectomy incontinence--the artificial urinary sphincter and male sling. Nat Clin Pract Urol. Nov 2007;4(11):615-24. [Medline].

  12. Foster P. Bladder management post catheter. Nurs BC. Nov-Dec 1998;30(5):28-9. [Medline].

  13. Gleason DM, Reilly RJ, Kreuzer F. Apical suspension test. Urology. Sep 1980;16(3):284-5. [Medline].

  14. Hijaz A, Moy L, Vasavada SP. The Evaluation and Management of Postpostatectomy Urinary Incontinence. Current Clinical Urology: Management of Prostate Cancer. 2004.

  15. Ingber M, Nagaraju P and Diokno A. Incontinence in the Elderly. In: Macias-Nunez J, Cameron J, and Oreopoulus D. The Aging Kidney: In Health and Disease. 1. 1. New York, NY: Springer; 2008:293-306.

  16. James M, Jackson S, Shepherd A. Pure stress leakage symptomatology: is it safe to discount detrusor instability?. Br J Obstet Gynaecol. Dec 1999;106(12):1255-8. [Medline].

  17. Jones S. Promoting continence in older people. Elder Care. Nov 1999;11(8):34-8; quiz 39. [Medline].

  18. Lemack GE. Reversing the tide: emerging options for treating overactive bladder symptoms in women. Tex Med. Nov 1999;95(11):78-81. [Medline].

  19. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. Mar-Apr 2001;7(2):342-7. [Medline].

  20. Maloney C, Cafiero M. Implementing an incontinence program in long-term care settings. A multidisciplinary approach. J Gerontol Nurs. Jun 1999;25(6):47-52. [Medline].

  21. Mersfelder TL. Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. Cleve Clin J Med. Mar 2001;68(3):208-9, 213-9, 223. [Medline].

  22. Ouslander JG, Cooper E, Godley D. Estrogen treatment for incontinence in frail older women. J Am Geriatr Soc. Nov 1999;47(11):1383-4. [Medline].

  23. Rackley RR. Office Evaluation of Urinary Incontinence. Contemporary Therapy in Obstetrics and Gynecology: Issues and Controversies. 2000.

  24. Rackley RR, Abdelmalak JB. Management of Female Urinary Incontinence. Essential Urology: A Guide to Clinical Practice. 2004;8:153-167.

  25. Rackley RR, Appell RA. Evaluation and medical management of female urinary incontinence. Cleve Clin J Med. Feb 1997;64(2):83-92. [Medline].

  26. Saint S, Elmore JG, Sullivan SD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. Sep 1998;105(3):236-41. [Medline].

  27. Saint S, Lipsky BA, Baker PD. Urinary catheters: what type do men and their nurses prefer?. J Am Geriatr Soc. Dec 1999;47(12):1453-7. [Medline].

  28. Sander P, Mouritsen L, Andersen JT. Evaluation of a simple, non-surgical concept for management of urinary incontinence (minimal care) in an open-access, interdisciplinary incontinence clinic. Neurourol Urodyn. 2000;19(1):9-17. [Medline].

  29. Vasavada SP, Rackley RR. Electrical Stimulation for Storage and Emptying Disorders. Campbell's Urology. 2006.

  30. Vasavada SP, Rackley RR. How Effective is Pharmocotherapy for Overactive Bladder. Patient Care. 2006;40(1):40-46.

  31. Visco AG, Weidner AC, Cundiff GW. Observed patient compliance with a structured outpatient bladder retraining program. Am J Obstet Gynecol. Dec 1999;181(6):1392-4. [Medline].

  32. [Best Evidence] Fink HA, Taylor BC, Tacklind JW, Rutks IR, Wilt TJ. Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. Mayo Clin Proc. Dec 2008;83(12):1332-43. [Medline].

  33. [Best Evidence] Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. Jan 29 2009;360(5):481-90. [Medline].

Further Reading

Keywords

incontinence, urinary incontinence, functional incontinence, stress incontinence, urge incontinence, overflow incontinence, mixed incontinence, reflex incontinence, Foley catheter, decompensated bladder, detrusor instability, Marshall test, Kegel exercises, detrusor hyperreflexia, overactive bladder, urinary tract infections, UTI, underpads, pant liners, shields and guards, adult diapers, disposable pad systems, urethral occlusive devices, indwelling urethral catheters, suprapubic catheters, intermittent catheterization

Contributor Information and Disclosures

Author

Raymond Rackley, MD, Professor of Surgery, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Staff Physician, Center for Pelvic Medicine and Pelvic Reconstruction, Glickman Urological Institute, Cleveland Clinic Foundation
Raymond Rackley, MD is a member of the following medical societies: American Urological Association
Disclosure: Pfizer, Novartis, Proctor & Gamble, Allergan Honoraria None; Pfizer, Novartis, Proctor & Gamble, Allergan Consulting fee Other

Coauthor(s)

Sandip P Vasavada, MD, Physician, Center for Female Pelvic Medicine and Genitourinary Reconstructive Surgery, The Glickman Urological and Kidney Institute; Joint Appointment with Women's Institute, Cleveland Clinic
Sandip P Vasavada, MD is a member of the following medical societies: American Urogynecologic Society, American Urological Association, International Continence Society, and Society for Urology and Engineering
Disclosure: pfizer Honoraria Speaking and teaching; allergan Consulting fee Consulting; ndi medical, LLC Ownership interest Review panel membership; novartis Honoraria Speaking and teaching

Michael S Ingber, MD, Clinical Fellow, Glickman Urological and Kidney Institute of the Cleveland Clinic
Disclosure: Nothing to disclose.

Farzeen Firoozi, MD, Clinical Fellow, Center for Female Urology and Pelvic Reconstructive Surgery, Glickman Urological and Kidney Institute of the Cleveland Clinic
Farzeen Firoozi, MD is a member of the following medical societies: American Medical Association and American Urological Association
Disclosure: Nothing to disclose.

Medical Editor

Martha K Terris, MD, FACS, Professor, Department of Surgery, Medical College of Georgia
Martha K Terris, MD, FACS is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Institute of Ultrasound in Medicine, American Urological Association, New York Academy of Sciences, and Society of University Urologists
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Mark Jeffrey Noble, MD, Consulting Staff, Urologic Institute, Cleveland Clinic Foundation
Mark Jeffrey Noble, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Kansas Medical Society, Sigma Xi, Society of University Urologists, and Southwest Oncology Group
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Omeros Corporation Consulting fee Consulting

Chief Editor

Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, and Tennessee Medical Association
Disclosure: Lilly Consulting fee Consulting; Astellas Consulting fee Speaking and teaching; Indevus Consulting fee Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.